GLP1R and type 2 diabetes mellitus: Tirzepatide had a lower ROR for GIAEs than GLP-1 receptor agonists but a higher ROR than non-GLP-1 drugs, with a greater risk in patients with type 2 diabetes (T2DM) than in those using tirzepatide for weight loss.<h4>Conclusion</h4>Tirzepatide is associated with an increased risk of GIAEs, particularly among patients with T2DM, males, older adults, and those using concomitant medications.